Idefirix has secured pricing and reimbursement in Sweden, the Netherlands and Germany, and on an individual hospital basis in Finland and Greece. Market access procedures are ongoing in 11 countries, including Spain, Italy and the U.K. France is also in an excellent position to contribute over the next 12 months based on the early access program. The reported product sales in Q1 are SEK 24m. With a positive outlook, this should be enough to trigger some near-term share price support. The Q1 is a step in the right direction as it escalates from the very early stage.

https://www.redeye.se/research/838880/hansa-biopharma-q1-the-early-european-launch-steps-up-a-gear?utm_source=finwire&utm_medium=RSS

Redeye